DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COLLEGE OF PHARMACY, UNIVERSITY OF KUFA, KUFA, IRAQ.
Wiad Lek. 2024;77(3):514-525. doi: 10.36740/WLek202403118.
Aim: To evaluate the cytotoxic activity of newly synthesized a series of novel HDAC inhibitors comprising sulfonamide as zinc binding group and Coumarin as cap groups.
Materials and Methods: The utilization of sulfonamide as zinc binding group and Coumarin as cap groups known to possess antitumor activity in the designed of new histone deacetylase inhibitors and using the docking and MTT assay to evaluate the compounds.
Results: Four compounds have been synthesized and characterized successfully by ART-FTIR, NMR and ESI-Ms. The synthesized compound assessed for their cytotoxic activity against hepatoblastoma HepG2 (IC50, I=0.094, II=0.040, III=0.032, IV=0.046, SAHA=0.141) and human colon adenocarcinoma MCF-7 (IC50, I=0.135, II=0.050, III= 0.065, IV=0.059, SAHA=0.107). The binding mode to the active site of [HDAC6] were determined by docking study which give results that they might be good inhibitors for [HDAC6].
Conclusions: The synthesized compounds (I, II, III and IV) showed a comparable cytotoxic result with FDA approved drug (SAHA) toward HepG2 and MCF-7 cancer cell lines and their docking analysis provided a preliminary indication that they are viable [HDAC6] candidates.
旨在评估新合成的一系列新型 HDAC 抑制剂的细胞毒性活性,这些抑制剂包含作为锌结合基团的磺酰胺和作为帽基团的香豆素。
材料和方法:在设计新的组蛋白去乙酰化酶抑制剂时,利用磺酰胺作为锌结合基团和香豆素作为帽基团,已知它们具有抗肿瘤活性,并使用对接和 MTT 测定法来评估这些化合物。
结果:成功地通过 ART-FTIR、NMR 和 ESI-Ms 合成并表征了四种化合物。评估了合成化合物对肝癌 HepG2(IC50,I=0.094,II=0.040,III=0.032,IV=0.046,SAHA=0.141)和人结肠腺癌 MCF-7(IC50,I=0.135,II=0.050,III=0.065,IV=0.059,SAHA=0.107)的细胞毒性活性。通过对接研究确定了与 [HDAC6] 活性位点的结合模式,结果表明它们可能是 [HDAC6] 的良好抑制剂。
结论:合成的化合物(I、II、III 和 IV)在 HepG2 和 MCF-7 癌细胞系中表现出与 FDA 批准药物(SAHA)相当的细胞毒性作用,并且它们的对接分析初步表明它们是可行的 [HDAC6] 候选物。